 | This articlerelies excessively onreferences toprimary sources. Please improve this article by addingsecondary or tertiary sources. Find sources: "Dapagliflozin/saxagliptin" – news ·newspapers ·books ·scholar ·JSTOR(July 2020) (Learn how and when to remove this message) |
| Combination of | |
|---|---|
| Dapagliflozin | SGLT-2 inhibitor |
| Saxagliptin | Dipeptidyl peptidase-4 inhibitor |
| Clinical data | |
| Trade names | Qtern |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category | |
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| KEGG | |
Dapagliflozin/saxagliptin, sold under the brand nameQtern, is afixed-dose combinationanti-diabetic medication used as an adjunct to diet and exercise to improveglycemic control in adults withtype 2 diabetes.[2][3] It is a combination ofdapagliflozin andsaxagliptin.[2][3] It is taken by mouth.[2][3]
The most common side effects include upper respiratory tract infection (such as nose and throat infections) and, when used with a sulphonylurea, hypoglycaemia (low blood glucose levels).[3]
Dapagliflozin/saxagliptin was approved for medical use in the European Union in July 2016, and in the United States in February 2017.[3][4]
In the United States, dapagliflozin/saxagliptin isindicated as an adjunct to diet and exercise to improveglycemic control in adults withtype 2 diabetes.[2]
In the European Union, it is indicated in adults aged 18 years and older with type 2 diabetes:
